The Motley Fool
27 Jun 2026, 16:11 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA has granted rolling review for Palvella Therapeutics' New Drug Application for QTORIN rapamycin in treating microcystic lymphatic malformations. — Rolling review accelerates the regulatory process, increasing the probability and speed of potential drug approval.
+0.60Palvella Therapeutics is on track to complete the NDA submission for QTORIN rapamycin in the second half of 2026. — Provides a clear timeline for a major catalyst event, though the date is significantly in the future.
+0.30COO Kathleen Goin sold approximately $476,000 worth of shares following the exercise of stock options via a Rule 10b5-1 trading plan. — Insider selling can be a bearish signal, but the use of a pre-planned 10b5-1 schedule mitigates the negative impact.
-0.10Continue reading
6 related stories
Top 1 mover · tap to explore
Palvella Therapeutics has moved its shares to the Nasdaq Global Market. — Listing on a major exchange typically increases liquidity and visibility for institutional investors.
+0.10Which stocks this story touches
The company has seen a massive stock surge, received FDA rolling review for its lead therapy, and successfully moved to the Nasdaq Global Market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
3h ago
